13 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
6 Jul 23
Current report (foreign)
6:18am
systems built on a fee- for-service model are facing significant financial and resource strain, and the restrictive drug pricing and reimbursement policies
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
23 Jun 23
Current report (foreign)
6:13am
on drug prices. At the same time, unpredictable and escalating payment rates under the U.K.’s drug pricing and reimbursement scheme raise concerns about
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:19am
, if governments can demonstrate improved efficiency and effectiveness in health care systems, the investment is more readily justifiable. The restrictive drug … pricing and reimbursement policies adopted in the EU and the U.K., coupled with persistent price reductions in Japan, raise concerns about the impact
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:11am
on drug prices. At the same time, unpredictable and escalating payment rates under the U.K.’s drug pricing and reimbursement scheme raise concerns about
6-K
TAK
Takeda Pharmaceutical Co
11 May 23
Current report (foreign)
6:07am
. At the same time, unpredictable and escalating payment rates under the U.K.’s drug pricing and reimbursement scheme raise concerns about the impact
6-K
EX-99.1
ttsd 8don
31 May 22
Current report (foreign)
6:14am
6-K
EX-99.1
2sgflruq
28 May 21
Current report (foreign)
6:04am
6-K
g7a668bjprn6i5
12 Feb 21
Current report (foreign)
6:04am
6-K
rrmq 50jhz2g3
13 Feb 20
Current report (foreign)
6:05am
20FR12B/A
khscypn9x8q
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
1piy3l4dk
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
thd92w0h971ftppd1yb
16 Nov 18
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next